This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q26.4 (anomalous pulmonary venous connection, unspecified) | Special Copayment Reduction: V192 (special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date) |
| B. Synonyms | Anomalous pulmonary venous connection NOS, Anomalous pulmonary venous connection NOS, anomalous pulmonary venous return, unspecified, APVC unspecified |
| C. Adult onset | This code is used when it is unclear whether the anomaly is partial or total, or when it has not been confirmed by imaging, and not a few cases are found incidentally in adulthood. After confirmation, it should be reclassified as Q26.2 or Q26.3. |
| 1. History | Development of the ICD code classification system; clinical use and evolution of unspecified codes |
| 2. Causes | Failure of the pulmonary venous confluence to join the left atrium; distinction between total and partial types not yet established because workup is incomplete |
| 3. Genetics | Shared genetic background with Q26.2 and Q26.3; associated with 22q11.2 deletion and NKX2.5 and GATA4 variants |
| 4. General epidemiology | Less than 1% of all congenital heart disease; unspecified codes are used with some frequency because of incomplete prenatal and postnatal imaging |
| 5. Pathophysiology | Oxygenated blood enters the right atrium, with left-to-right shunt or cyanosis; specific connection site and extent unknown |
| 6. Symptoms | The full symptom spectrum of both Q26.2 and Q26.3 is possible; ranges from cyanosis to no symptoms |
| 7. Signs | Fixed splitting of S2, heart murmur, right heart enlargement, cyanosis, etc., varying with the degree of the connection |
| 8. Screening | Newborn pulse oximetry, fetal echocardiography; classification confirmed by imaging when abnormal findings are present |
| 9. Diagnosis | Connection type confirmed by cardiac CT/MRI, reclassification and recoding essential; cardiac catheterization as an adjunct |
| 10. Treatment | After the classification is confirmed, surgical correction as for Q26.2 or Q26.3; immediate surgery in emergencies |
| 11. Prognosis | Falls within the prognostic range of TAPVC to PAPVC depending on the extent of the connection and the presence of obstruction |
| 12. Prevention | Strengthened prenatal testing, newborn screening and rapid imaging classification to prevent treatment delays |
| 13. References | Prevalence and pattern of total and partial anomalous pulmonary venous connection in Indian patients with congenital heart disease … and 9 other papers |
ICD (International Classification of Diseases) code Q26.4 is an administrative and clinical classification code used when an anomalous pulmonary venous connection is present but clinical information or imaging results are incomplete, so it cannot be subclassified as total (Q26.2) or partial (Q26.3). To understand why this code exists, the historical context of anomalous pulmonary venous connection as a whole should be examined.
The first systematic descriptions of anomalous pulmonary venous connection came from European anatomists in the 18th–19th centuries. After Wilson's first record in 1798, classification based on autopsy findings predominated until the first half of the 20th century. Before antemortem diagnostic techniques developed, it was often difficult to distinguish the total and partial types clinically, and this historical background provides the rationale for the use of an "unspecified" code.
In 1957 Darling et al. systematized the anatomical classification of TAPVC, and criteria for distinguishing it from PAPVC were subsequently established. In the World Health Organization (WHO) ICD-10 revision (1990s), the Q26 category was subdivided into Q26.2 (total), Q26.3 (partial) and Q26.4 (unspecified). Q26.4 is used for provisional coding especially in resource-limited settings, in emergencies and when imaging is incomplete.
Today, with the spread of high-resolution imaging such as cardiac CT, MRI and transesophageal echocardiography, cases remaining as Q26.4 are decreasing. However, it is still used in complex cardiac malformations with unclear imaging interpretation, in settings where test data from multiple institutions are incompletely shared, and when no autopsy is performed after infant death. Use of the Q26.4 code must be accompanied by a clinical process ensuring reclassification as Q26.2 or Q26.3 through further testing.
In ICD-11 the classification of anomalous pulmonary venous connection has been further subdivided, and standardization of clinical information collection is emphasized. This reflects the direction of health information standards that use of "unspecified" codes should be minimized and the precise anatomical subtype should be coded.
The causes of Q26.4 are fundamentally the same as those of Q26.2 (TAPVC) and Q26.3 (PAPVC). That is, it arises when the process by which the primitive common pulmonary vein normally joins the posterior wall of the left atrium at 4–5 weeks of embryonic development fails totally or partially. The number and anatomical location of the anomalously connected veins distinguish the total and partial types, and Q26.4 denotes the state in which this distinction has not been made.
The main situations in which Q26.4 is used in clinical practice are, first, when emergency neonatal surgery was performed before imaging could be adequately carried out; second, when imaging classification was not completed before death in infancy; third, when testing is incomplete during outpatient follow-up; and fourth, when a provisional code entered in the electronic medical record was retained as the final code.
Environmental and genetic risk factors apply in the same way as for Q26.2 and Q26.3. Risk factors include rubella virus infection in early pregnancy, maternal diabetes and exposure to teratogenic drugs (retinoids, anticonvulsants), and with accompanying asplenia or polysplenia, TAPVC is more likely.
The genetic background of anomalous pulmonary venous connection coded as Q26.4 is shared with Q26.2 and Q26.3. 22q11.2 microdeletion (DiGeorge syndrome) is the best known chromosomal cause, and patients with this deletion have an increased frequency of abnormal pulmonary venous development. Heterozygous variants in cardiac transcription factor genes such as NKX2.5 and GATA4 are associated with familial congenital heart disease, and anomalous pulmonary venous connection is included in that spectrum.
CFC1 (cytokine-related protein) and ACVR1 variants sometimes occur together with TAPVC in heterotaxy syndrome, suggesting that pulmonary venous development is closely linked to determination of the cardiac left-right axis. At the molecular level, abnormalities of the Notch, BMP and TGF-β signaling pathways have been proposed to be related to failed pulmonary venous development. Most cases are sporadic, but familial recurrence (sibling recurrence risk about 2–4%) has been reported.
The prevalence of anomalous pulmonary venous connection overall is about 7 per 100,000 live births, and some of these are initially coded as Q26.4. Because they are subsequently reclassified as Q26.2 or Q26.3 based on imaging results, the proportion in which the Q26.4 code actually remains as the final diagnosis is low. The rate at which Q26.4 remains as the final code is even lower in medically advanced countries and relatively higher in resource-limited settings.
An Indian multicenter study (Saxena et al., 2015) analyzed a congenital heart disease database and described the frequency and patterns of TAPVC and PAPVC, and this study also included some cases with an unclassified connection type. Worldwide, as newborn pulse oximetry screening and echocardiography become more widespread, use of the unspecified code is declining.
The pathophysiology of Q26.4 should be understood as a spectrum encompassing the pathophysiology of both Q26.2 and Q26.3, in that the number and location of the anomalously connected pulmonary veins are unclear. The closer it is to the total type, the more likely there is complete mixing of blood in the right atrium, severe cyanosis and accompanying pulmonary venous obstruction. The closer it is to the partial type, the more the main pathophysiology is right heart volume overload from a left-to-right shunt and progressive pulmonary vascular disease.
In either case there is a common mechanism in which oxygenated blood from the pulmonary veins flows into the right atrium, so systemic oxygen delivery decreases (total type) or the volume load on the right heart increases (partial type). The size of an accompanying ASD and the presence of pulmonary venous obstruction are the key factors determining clinical severity.
The symptom spectrum ranges widely, from the severe cyanosis of Q26.2 (TAPVC) to the absence of symptoms or mild exercise intolerance of Q26.3 (PAPVC). While the diagnostic code remains Q26.4, the clinician should assume the worst case (total type with obstruction) when evaluating and treating the patient.
In newborns, tachypnea, feeding difficulty, cyanosis and pulmonary edema are signals requiring urgent intervention. In children and adults, recurrent respiratory infections, exercise intolerance, palpitations and symptoms of right heart failure may appear. When treatment is given while in the Q26.4 state, it is important to confirm the classification through imaging as soon as possible and to establish an appropriate surgical plan.
Physical examination findings vary with the extent of the anomalous connection and the presence of obstruction. An accentuated and fixed split second heart sound and a systolic murmur in the pulmonary area are common. When it is closer to the total type, central cyanosis, digital clubbing and signs of respiratory failure are prominent. When it is closer to the partial type, signs of right heart volume overload, such as a right ventricular heave, a murmur at the right sternal border and hepatomegaly, are the main findings.
Chest X-ray may show cardiomegaly, increased pulmonary vascular markings or pulmonary edema, and the ECG shows right axis deviation, right ventricular hypertrophy and incomplete right bundle branch block. When the Q26.4 code is used, active imaging diagnosis is needed to determine the cause of these nonspecific findings.
Newborn pulse oximetry screening and fetal echocardiography are the key tools for early detection of anomalous pulmonary venous connection. Detailed echocardiography is performed when SpO₂ is below 95% or the difference between upper and lower limbs is 3% or more, and when an abnormality is found, the classification as Q26.2 or Q26.3 should be confirmed immediately by imaging.
When transthoracic echocardiography shows right heart enlargement, a small left atrium and suspected anomalous pulmonary venous connection, it is provisionally coded as Q26.4 and confirmed by cardiac CT or MRI. Even if imaging is delayed, testing for anatomical classification should proceed together with clinical stabilization.
Cardiac CT angiography and cardiac MRI are the standard tests that reconstruct the pulmonary venous connection in three dimensions to distinguish the total and partial types. Cardiac CT has the advantages of short scan time and high spatial resolution, and cardiac MRI additionally provides hemodynamic indices (Qp:Qs, right ventricular function) without radiation. Both tests are essential for the definitive classification of Q26.4.
Transesophageal echocardiography (TEE) shows high sensitivity for direct visualization of the pulmonary venous orifices and complements diagnosis when cardiac CT or MRI is not possible. Cardiac catheterization is performed when measurement of pulmonary vascular resistance and Qp:Qs or preoperative hemodynamic evaluation is needed. Patients coded as Q26.4 must undergo at least one of the above imaging tests to confirm the final code.
Treatment of patients coded as Q26.4 is decided according to clinical severity and imaging findings. With accompanying pulmonary venous obstruction or severe cyanosis, emergency surgical correction is needed, and even if imaging classification has not been completed before surgery, correction is performed after direct anatomical confirmation during the operation.
In stable cases, imaging is first completed to confirm the classification as Q26.2 or Q26.3, and surgical correction is then planned according to the guidelines for that disease. If the total type is confirmed, early correction is the rule; if the partial type is confirmed, correction is performed when Qp:Qs ≥1.5 and right ventricular enlargement are present. Preoperative management includes diuretics, oxygen and, when needed, mechanical ventilation and prostaglandin E1.
Prognosis is determined by the final confirmed classification (total or partial), the presence of pulmonary venous obstruction and the timing of surgery. When the total type is confirmed and early surgical correction is performed, 5-year survival reaches 85–90%, and for the partial type long-term survival after correction is similar to that of the general population. The longer diagnosis and classification are delayed, the more pulmonary vascular disease progresses and the worse the prognosis may become, so prompt definitive classification of the Q26.4 state directly affects prognosis.
In long-term follow-up, pulmonary vein restenosis (after correction of the total type), atrial fibrillation, residual pulmonary hypertension and right ventricular dysfunction are items to monitor. Regular follow-up by a cardiologist is essential even after surgery.
The principles of prevention for Q26.4 are the same as for Q26.2 and Q26.3. Prenatal fetal echocardiography, newborn pulse oximetry screening, genetic counseling, prevention of maternal infection, diabetes control and avoidance of teratogenic drugs are recommended. In addition, definitive classification through prompt imaging and specialist conferences is needed as a "preventive" measure at the health system level so that the Q26.4 state does not persist.
It is recommended that medical institutions operate a protocol for completing definitive classification within a defined period (e.g., 30 days) after Q26.4 coding of congenital heart disease. Early definitive classification is a key strategy for preventing treatment delays and improving patient outcomes.
Saxena A, Mehta A, Juneja R, et al. Prevalence and pattern of total and partial anomalous pulmonary venous connection in Indian patients with congenital heart disease. Ann Pediatr Cardiol. 2015;8(1):10-15. DOI: 10.4103/0974-2069.149515. PMID: 25684884.
Seale AN, Uemura H, Webber SA, et al. Total anomalous pulmonary venous connection: morphology and outcome from an international population-based study. Circulation. 2010;122(25):2718-2726. DOI: 10.1161/CIRCULATIONAHA.110.940825. PMID: 21135366.
Darling RC, Rothney WB, Craig JM. Total pulmonary venous drainage into the right side of the heart. Lab Invest. 1957;6(1):44-64. PMID: 13400070.
Shuler CO, Black GB, Jerrell JM. Population-based treated prevalence of congenital heart disease in a pediatric cohort. Pediatr Cardiol. 2013;34(3):606-611. DOI: 10.1007/s00246-012-0469-6. PMID: 22871991.
Karamlou T, Gurofsky R, Al Sukhni E, et al. Factors associated with mortality and reoperation in 377 children with total anomalous pulmonary venous connection. Circulation. 2007;115(12):1591-1598. DOI: 10.1161/CIRCULATIONAHA.106.635581. PMID: 17353443.
Lacour-Gayet F, Zoghbi J, Serraf AE, et al. Surgical management of progressive pulmonary venous obstruction after repair of total anomalous pulmonary venous connection. J Thorac Cardiovasc Surg. 1999;117(4):679-687. DOI: 10.1016/s0022-5223(99)70289-4. PMID: 10096964.
Ammash NM, Seward JB, Warnes CA, et al. Partial anomalous pulmonary venous connection: diagnosis by transesophageal echocardiography. J Am Coll Cardiol. 1997;29(6):1351-1358. DOI: 10.1016/s0735-1097(97)82758-1. PMID: 9137235.
Kouchoukos NT, Blackstone EH, Hanley FL, Kirklin JK. Kirklin/Barratt-Boyes Cardiac Surgery. 4th ed. Philadelphia: Elsevier Saunders; 2013. Chapter on anomalous pulmonary venous connection. ISBN: 978-1-4160-6391-9.
Yun TJ, Coles JG, Konstantinov IE, et al. Conventional and sutureless techniques for management of the pulmonary veins. J Thorac Cardiovasc Surg. 2005;129(1):167-174. DOI: 10.1016/j.jtcvs.2004.05.041. PMID: 15632841.
Vida VL, Padalino MA, Boccuzzo G, et al. Scimitar syndrome: a European Congenital Heart Surgeons Association (ECHSA) multicentric study. Circulation. 2010;122(12):1159-1166. DOI: 10.1161/CIRCULATIONAHA.109.926204. PMID: 20823381.